Navigation Links
SuperGen Reports 2008 Third Quarter Financial Results
Date:11/4/2008

rating expenses by up to $1 million annually. Stock-based compensation expense, which is included in operating expenses, was $642,000 for the 2008 third quarter compared with $904,000 for the same prior year period.

There was no gain on sale of products for the 2008 third quarter compared with $1.8 million for the same prior year period. The gain on sale of products for the 2007 third quarter related to the receipt of a milestone payment in the amount of $1.8 million due to the achievement of Nipent(R) (pentostatin for injection) sales targets by Mayne Pharma (acquired by Hospira, Inc. in February 2007).

Loss from operations for the 2008 third quarter was $1.1 million compared with $1.3 million for the same prior year period. The Company reported a net loss for the 2008 third quarter of $569,000, or $0.01 per fully diluted share, compared with net income of $192,000, or $0.00 per fully diluted share, for the same prior year period. The net loss for the 2008 third quarter includes an income tax benefit of $42,000 compared with $427,000 for the same prior year period.

"In a troublesome economic climate, particularly for biotechnology companies in SuperGen's valuation range, our third quarter and year-to-date financial performance was positive," said James S. Manuso, Ph.D., President and Chief Executive Officer. "Our cash, cash equivalents and marketable securities at the end of the third quarter was approximately $88.7 million dollars. We continue to manage our financial resources to maximize the impact every dollar has on our drug discovery and development objectives. Our operational results for the quarter include the clinical advancement of MP-470, our oral tyrosine kinase inhibitor, and further preparations for entering SGI-1776, our oral PIM kinase inhibitor, into Phase 1 clinical trials."

Total revenues for the nine months ended September 30, 2008 were $26.5 million compared with $15.2 million for the same prior year period. Total rev
'/>"/>

SOURCE SuperGen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Dr. Audrey F. Jakubowski of SuperGen Retires as Chief Regulatory and Quality Officer
2. SuperGen to Present at Thomas Weisel Partners Healthcare Conference September 5th
3. SuperGen to Announce 2007 Fourth Quarter and Fiscal Year-End Financial Results March 3, 2008
4. SuperGen Reports 2007 Fourth Quarter and Annual Financial Results
5. SuperGen to Announce 2008 First Quarter Financial Results April 28, 2008
6. SuperGen to Webcast 3rd Annual Analyst Day on April 29, 2008
7. SuperGen Reports 2008 First Quarter Financial Results
8. SuperGen to Present at FBR Capital Markets 12th Annual Spring Investor Conference on May 29, 2008
9. SuperGen Reports 2008 Second Quarter Financial Results
10. SuperGen to Present at Merriman 5th Annual Investor Summit on September 15, 2008
11. SuperGen to Present Data at EORTC-NCI-AACR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... and NEW YORK , ... from its open-label pilot study of mazindol in children ... Development and Therapy in December 2014 . ... mazindol in children with attention deficit/hyperactivity disorder" ( Konofal ... 2014 Dec 1;8:2321-2332. eCollection 2014 ) shows ...
(Date:12/22/2014)... Dec. 22, 2014 GenomeDx Biosciences today announced ... Cancer Classifier, a genomic test for prostate cancer, was ... men managed by radical prostatectomy without adjuvant therapy. Although ... relatively uncommon, using tumor genomics to identify these men ... is an important advance. The study has been ...
(Date:12/19/2014)... PA (PRWEB) December 19, 2014 ... leading developer and manufacturer of needle-free injection technology, ... agreement with Immunomic Therapeutics, Inc. (“ITI”) for ITI ... device with its LAMP™ vaccine platform. , ... an exclusive Worldwide license to the Biojector®-2000 that ...
(Date:12/19/2014)... Bina Technologies, Inc. (Bina, Redwood ... have been acquired by Roche (SIX: RO, ROG; OTCQX: ... company that provides a big data platform for centralized ... for the academic and translational research markets.  Bina will ... continue to focus on development of their innovative genomic ...
Breaking Biology Technology:Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3
... , , AIX-EN-PROVENCE, France, ... received 510K Clearance from the FDA for its Aixplorer(TM) ultrasound ... in the United States. Aixplorer is the only commercially ... based upon interaction between conventional longitudinal waves and shear waves ...
... CAMBRIDGE, Mass., Aug. 25 Peptimmune, Inc., a ... clinical trial to evaluate the safety, tolerability, pharmacokinetics, and ... Sclerosis (SP-MS). PI-2301 is a novel peptide copolymer ... diseases. , , The Phase Ib ...
... ... An Innovative Treatment for Multiple Sclerosis and Other Autoimmune Diseases , ... New York, NY/Rockville, MD (Vocus) August ... National Multiple Sclerosis Society,s subsidiary devoted to bridging the gap between research and drug ...
Cached Biology Technology:SuperSonic Imagine Receives FDA Approval for Aixplorer Ultrasound System 2SuperSonic Imagine Receives FDA Approval for Aixplorer Ultrasound System 3SuperSonic Imagine Receives FDA Approval for Aixplorer Ultrasound System 4Peptimmune Completes Phase Ib Study of PI-2301 in Multiple Sclerosis Patients, and Presentation at ECTRIMS 2009 2Peptimmune Completes Phase Ib Study of PI-2301 in Multiple Sclerosis Patients, and Presentation at ECTRIMS 2009 3Fast Forward, LLC and Amplimmune, Inc. Join Forces to Speed New Treatments to People with MS** 2Fast Forward, LLC and Amplimmune, Inc. Join Forces to Speed New Treatments to People with MS** 3Fast Forward, LLC and Amplimmune, Inc. Join Forces to Speed New Treatments to People with MS** 4
(Date:12/17/2014)... DENVER , Dec. 16, 2014  Automation ... is this more evident than at international borders. ... secure document scanners have allowed veteran travelers to ... Automated Passport Control (APC) Kiosks at an increasing ... the globe. According to ...
(Date:12/11/2014)... --Research and Markets , ... ) has announced the addition of the ... to their offering. One major ... technology. With continuous advances in technology, it is ... standard that meets the needs and expectations of ...
(Date:12/11/2014)... Dec. 10, 2014  That blood pressure plays a role ... Hypertension – the medical term for high blood pressure – ... and the inflatable cuff that,s used in measuring blood pressure ... there,s nothing new about hypertension, its triggers and its effects. ... the condition and the best ways to treat it. ...
Breaking Biology News(10 mins):Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
... CITY, Aug. 31, 2009 Researchers at Huntsman Cancer Institute ... on Ewing,s sarcoma, an often deadly bone cancer that typically ... with poor outcomes have tumors with high levels of a ... chemotherapy. The research is published online today in the journal ...
... its usefulness in counting copies of duplicated genome sequences and ... study to be published Aug. 30 in Nature Genetics ... differ from one person to the next. The researchers ... Search Tool. The study is titled, "Personalized Copy Number and ...
... on the neural mechanisms involved in social behavior, neuroscientists ... the brain structure responsible for our sense of personal ... 30 issue of the journal Nature Neuroscience , ... social distance is an issue. The structure, the ...
Cached Biology News:New hope for deadly childhood bone cancer 2Counting duplicated genome segments now possible 2Counting duplicated genome segments now possible 3Caltech neuroscientists find brain region responsible for our sense of personal space 2Caltech neuroscientists find brain region responsible for our sense of personal space 3Caltech neuroscientists find brain region responsible for our sense of personal space 4
Rabbit polyclonal antibody to NMDA NR2B [Tyr1336]...
... Reagent A: MTT, (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrasodium bromide), ... that is cleaved by living cells to ... process requires active mitochondria, and even freshly ... of MTT. Reagent A is a component ...
Mouse polyclonal antibody to ALS2CR8 - amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 8...
Determin interaction of your protein with Echelons lipids...
Biology Products: